Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Addresses Pre-Submission Meetings In Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

With the draft guidelines, FDA takes a step toward fulfilling one of its commitments under the reauthorized device user fee program to establish a more structured process for pre-submission meetings with industry.

Advertisement

Related Content

Mass-Spec Dx Makers Should Look To FDA's Multiplex, Multivariate Approach For Regulatory Tips
FDA MDUFA III Performance, By The Numbers
Regulatory Briefs: Pre-Submission Program Final Guidance; FDA Meetings; HHS Health IT Nominations
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
Industry Says FDA Should Broaden Scope Of Pre-Submission Program
Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees
FDA, Industry Haggle Over Price For New User Fee Deal

Topics

Advertisement
UsernamePublicRestriction

Register

MT031387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel